<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751461</url>
  </required_header>
  <id_info>
    <org_study_id>CSD210202</org_study_id>
    <nct_id>NCT04751461</nct_id>
  </id_info>
  <brief_title>CSD210202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems</brief_title>
  <official_title>CSD210202: An Unblinded, Randomized, Crossover, Confinement Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAI Services Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAI Services Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, 5-way crossover study designed to evaluate plasma nicotine&#xD;
      pharmacokinetic (PK) parameters following an ad libitum use of Electronic Nicotine Delivery&#xD;
      System (ENDS) investigational products (IPs) in a confinement setting by generally healthy&#xD;
      combustible cigarette (CC) smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential subjects will complete a pre-screening interview and a Screening Visit to assess&#xD;
      their eligibility within 45 days prior to enrollment, randomization and confinement.&#xD;
&#xD;
      Following the Screening Visit, eligible subjects will be scheduled for a check-in and&#xD;
      randomization visit. At the check-in and randomization visit, subjects' continued eligibility&#xD;
      will be confirmed prior to being randomized to a product use sequence and beginning their 6&#xD;
      nights and 7 days of confinement.&#xD;
&#xD;
      Starting on study Day 1, subject will start a Pre-study ENDS IP Acclimation Period through&#xD;
      Day 2. Subjects will be asked to acclimate to each of the ENDS IP at least once, while having&#xD;
      access to their usual brand (UB) cigarettes for ad libitum use. Starting on Day 3, subjects&#xD;
      will participate in five separate Test Sessions for nicotine PK assessment, one for each ENDS&#xD;
      IP. For approximately a half day prior to each respective Test Session (starting on Day 2),&#xD;
      subjects will use their assigned ENDS IP for the following day's Test Session at least twice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">April 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCnic0-240</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Baseline-adjusted area under the plasma nicotine concentration-versus-time curve from time zero to 240 minutes after the start of IP use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>240 minutes</time_frame>
    <description>Maximum baseline-adjusted plasma concentration of nicotine</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Smoking</condition>
  <condition>Smoking Behaviors</condition>
  <condition>Tobacco Use</condition>
  <condition>Tobacco Smoking</condition>
  <arm_group>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (ABECD) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (BCADE) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (CDBEA) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (DECAB) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (EADBC) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (DCEBA) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EDACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (EDACB) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (AEBDC) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (BACED) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 5 products (CBDAE) during an evaluation period, followed by a 4 hour Test Session</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product A</intervention_name>
    <description>P0213420, a 1.8% nicotine ENDS product</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product B</intervention_name>
    <description>P0213520, a 1.8% nicotine ENDS product</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product C</intervention_name>
    <description>P0211220, a 1.8% nicotine ENDS product</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product D</intervention_name>
    <description>P0211820, a 1.8% nicotine ENDS product</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product E</intervention_name>
    <description>P0213417, a 2.4% nicotine ENDS product</description>
    <arm_group_label>Product usage order ABECD</arm_group_label>
    <arm_group_label>Product usage order AEBDC</arm_group_label>
    <arm_group_label>Product usage order BACED</arm_group_label>
    <arm_group_label>Product usage order BCADE</arm_group_label>
    <arm_group_label>Product usage order CBDAE</arm_group_label>
    <arm_group_label>Product usage order CDBEA</arm_group_label>
    <arm_group_label>Product usage order DCEBA</arm_group_label>
    <arm_group_label>Product usage order DECAB</arm_group_label>
    <arm_group_label>Product usage order EADBC</arm_group_label>
    <arm_group_label>Product usage order EDACB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand, and willing to sign an informed consent form (ICF) and&#xD;
             complete questionnaires written in English.&#xD;
&#xD;
          2. Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of&#xD;
             consent.&#xD;
&#xD;
          3. Expired breath carbon monoxide level is ≥ 10 ppm and ≤ 100 ppm at Screening.&#xD;
&#xD;
          4. Positive urine cotinine test at Screening.&#xD;
&#xD;
          5. Smokes only filtered, menthol or non-menthol combustible cigarettes, 83 mm to 100 mm&#xD;
             in length.&#xD;
&#xD;
          6. Agrees to smoke same UB combustible cigarette throughout the study period. UB&#xD;
             combustible cigarette is defined as the cigarette brand style currently smoked most&#xD;
             frequently by the subject.&#xD;
&#xD;
          7. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least&#xD;
             6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt&#xD;
             (prior to 30 days of Screening), or clinical study participation (prior to 30 days of&#xD;
             Screening) will be allowed at the discretion of the Principal Investigator (PI).&#xD;
&#xD;
          8. Willing to use only UB combustible cigarette and ENDS during the study period.&#xD;
&#xD;
          9. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each&#xD;
             Test Session.&#xD;
&#xD;
         10. Females must be willing to use a form of contraception acceptable to the PI from the&#xD;
             time of signing informed consent until End-of-Study.&#xD;
&#xD;
         11. Agrees to in-clinic confinement of 7 days and 6 nights.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal,&#xD;
             hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological&#xD;
             disease, or any other concurrent disease or medical condition that, in the opinion of&#xD;
             the PI, makes the study subject unsuitable to participate in this clinical study.&#xD;
&#xD;
          2. History, presence of, or clinical laboratory test results indicating diabetes.&#xD;
&#xD;
          3. Systolic blood pressure of &gt; 160 mmHg or a diastolic blood pressure of &gt; 95mmHg,&#xD;
             measured after being seated for five minutes.&#xD;
&#xD;
          4. Weight of ≤ 110 pounds.&#xD;
&#xD;
          5. Hemoglobin level is &lt; 12.5 for females or &lt;13.0 for males g/dL at Screening.&#xD;
&#xD;
          6. Scheduled treatment for asthma currently or within the past consecutive 12 months&#xD;
             prior to the Screening Visit. As-needed treatment, such as inhalers, may be included&#xD;
             at the PI's discretion pending approval from the Medical Monitor.&#xD;
&#xD;
          7. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
          8. Any history of cancer, except for primary cancers of skin such as localized basal&#xD;
             cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.&#xD;
&#xD;
          9. Use of an ENDS or tobacco or nicotine-containing products other than cigarettes (e.g.,&#xD;
             lozenges, moist snuff) within (≤) 30 days prior to Screening.&#xD;
&#xD;
         10. Use of any medication or substance that aids in smoking cessation, including but not&#xD;
             limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®),&#xD;
             bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to the&#xD;
             signing of informed consent.&#xD;
&#xD;
         11. History or presence of bleeding or clotting disorders.&#xD;
&#xD;
         12. Any use of anticoagulants or aspirin (≥ 325 mg/day).&#xD;
&#xD;
         13. Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed&#xD;
             consent.&#xD;
&#xD;
         14. Plasma donation within (≤) 7 days prior to the signing of informed consent.&#xD;
&#xD;
         15. Plans to donate whole blood or plasma prior to Enrollment and Study Day 1.&#xD;
&#xD;
         16. Participation in another clinical trial within (≤) 30 days prior to the signing of&#xD;
             informed consent. The 30-day window for each subject will be derived from the date of&#xD;
             the last study event in the previous study to the time of signing the ICF in the&#xD;
             current study.&#xD;
&#xD;
         17. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
         18. Individuals ≥ 35 years of age currently using systemic, estrogen-containing&#xD;
             contraception or hormone replacement therapy.&#xD;
&#xD;
         19. A positive urine drug screen without evidence of prescribed corresponding concomitant&#xD;
             medication(s) at Screening or Day 1.&#xD;
&#xD;
         20. Postpones a decision to quit using tobacco- or nicotine-containing products in order&#xD;
             to participate in this study or a previous attempt within (≤) 30 days prior to the&#xD;
             signing of the ICF.&#xD;
&#xD;
         21. Drinks more than 21 servings of alcoholic beverages per week or has a positive alcohol&#xD;
             breathalyzer result at Screening or Day 1.&#xD;
&#xD;
         22. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or&#xD;
             nicotine-containing products as part of their job.&#xD;
&#xD;
         23. Determined by the PI to be inappropriate for this study. *Subjects will be advised&#xD;
             against scheduling of whole blood or plasma donation following study completion for at&#xD;
             least 7 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Hong, MD</last_name>
    <role>Study Director</role>
    <affiliation>RAIS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen Prevette, BA</last_name>
    <phone>336-741-1873</phone>
    <email>prevetk1@rjrt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AMR Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

